Patents by Inventor Olga Vasiljeva

Olga Vasiljeva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240337658
    Abstract: The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.
    Type: Application
    Filed: November 9, 2023
    Publication date: October 10, 2024
    Inventors: Olga VASILJEVA, Elizabeth-Edna Mary MENENDEZ
  • Patent number: 12049505
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP) or at least one cysteine protease (CP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease or at least one cysteine protease (CP), and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease or at least one cysteine protease (CP) in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: July 30, 2024
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Olga Vasiljeva, Michael B. Winter
  • Publication number: 20240239904
    Abstract: The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.
    Type: Application
    Filed: January 17, 2024
    Publication date: July 18, 2024
    Applicant: CytomX Therapeutics, Inc.
    Inventors: Olga VASILJEVA, Michael B. WINTER
  • Publication number: 20240150478
    Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: September 25, 2023
    Publication date: May 9, 2024
    Inventors: Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel R. HOSTETTER, Olga VASILJEVA, Jeanne Grace FLANDEZ
  • Publication number: 20240150402
    Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 8, 2023
    Publication date: May 9, 2024
    Inventors: Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA
  • Publication number: 20240084022
    Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: September 25, 2023
    Publication date: March 14, 2024
    Inventors: Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel R. HOSTETTER, Olga VASILJEVA, Jeanne Grace FLANDEZ
  • Patent number: 11890354
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: February 6, 2024
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Patent number: 11884746
    Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: January 30, 2024
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva
  • Patent number: 11867695
    Abstract: The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: January 9, 2024
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Patent number: 11814410
    Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: November 14, 2023
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel R. Hostetter, Olga Vasiljeva, Jeanne Grace Flandez
  • Publication number: 20230212283
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 7, 2022
    Publication date: July 6, 2023
    Applicant: Cytomx Therapeutics, Inc.
    Inventors: Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA, Jason Gary SAGERT, Jonathan Alexander TERRETT, James William WEST
  • Publication number: 20230021301
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: June 28, 2021
    Publication date: January 19, 2023
    Applicant: CytomX Therapeutics, Inc.
    Inventors: Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA, Jason Gary SAGERT, Jonathan Alexander TERRETT, James William WEST
  • Patent number: 11548943
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: January 10, 2023
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West
  • Patent number: 11548944
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: January 10, 2023
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West
  • Publication number: 20220411470
    Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: April 26, 2021
    Publication date: December 29, 2022
    Applicant: CytomX Therapeutics, Inc.
    Inventors: Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA
  • Publication number: 20220380453
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: June 28, 2021
    Publication date: December 1, 2022
    Applicant: CytomX Therapeutics, Inc.
    Inventors: Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA, Jason Gary SAGERT, Jonathan Alexander TERRETT, James William WEST
  • Patent number: 11472875
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: October 18, 2022
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West
  • Publication number: 20220298245
    Abstract: The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: September 30, 2021
    Publication date: September 22, 2022
    Inventors: James William West, Li Mei, Stephen James Moore, Margaret T.L. Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett
  • Publication number: 20220226514
    Abstract: The present invention provides methods, compounds, and compositions useful for determining the in vivo distribution of a radionuclide after administering a radiolabeled activatable anti-CD166 antibody-bioactive agent conjugate to a subject by positron emission tomography imaging. The present invention also provides methods for identifying subjects suitable for treatment with the corresponding non-radiolabeled activatable anti-CD166-bioactive agent conjugates.
    Type: Application
    Filed: May 17, 2020
    Publication date: July 21, 2022
    Inventors: Olga VASILJEVA, Danielle J. VUGTS, Marion CHOMET, Catharina Willemien Menke-van der Houven VAN OORDT, Guus A.M.S. VAN DONGEN
  • Publication number: 20210382053
    Abstract: The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.
    Type: Application
    Filed: April 30, 2021
    Publication date: December 9, 2021
    Inventors: Olga VASILJEVA, Elizabeth-Edna Mary MENENDEZ